Holen Sie sich die Stockscreener-App
284.91
1.21%
-3.49
Handel nachbörslich:
284.91
Schlusskurs vom Vortag:
$288.40
Offen:
$286.25
24-Stunden-Volumen:
567.36K
Relative Volume:
0.72
Marktkapitalisierung:
$20.05B
Einnahmen:
$2.20B
Nettoeinkommen (Verlust:
$402.20M
KGV:
51.24
EPS:
5.56
Netto-Cashflow:
$280.80M
1W Leistung:
-1.83%
1M Leistung:
-5.03%
6M Leistung:
+2.35%
1J Leistung:
+44.44%
1-Tages-Spanne:
$282.75
$287.40
1-Wochen-Bereich:
$282.75
$300.24
52-Wochen-Spanne:
$173.00
$329.33
Insulet Corporation Stock (PODD) Company Profile
Firmenname
Insulet Corporation
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Vergleichen Sie PODD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
284.91 | 20.30B | 2.20B | 402.20M | 280.80M | 5.56 |
|
ABT
Abbott Laboratories
|
127.29 | 219.63B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.41 | 155.22B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
377.79 | 150.09B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.34 | 115.62B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.33 | 46.52B | 5.69B | 4.15B | 623.10M | 6.95 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-05-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corporation Aktie (PODD) Neueste Nachrichten
Insulet Corporation Stock (PODD) Opinions on Analyst 'Moderate Buy' Rating - Quiver Quantitative
How many analysts rate Insulet Corporation as a “Buy”Retirement Planning Review With Proven Results - jammulinksnews.com
What makes Insulet Corporation stock price move sharplyMarket Forecast Tracker For Smart Trading - jammulinksnews.com
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Why Insulet Corporation stock attracts strong analyst attentionAI Driven Entry Signal Review - beatles.ru
Insulet Corporation Company Revenue and Profit Trends: A Deep DiveLow Risk Buy Zone Opportunity Watch Ongoing - metal.it
Is Insulet (NASDAQ:PODD) Using Too Much Debt? - 富途牛牛
Insulet Corporation Flashes Buy Signal on Multi Timeframe ChartPrice Action Based Buy Opportunity List Published - metal.it
Fibonacci Retracement Aligns with Support in Insulet CorporationCapital Efficiency Optimized Stock Alerts Reviewed - metal.it
What catalysts could drive Insulet Corporation stock higher in 2025Low Risk Alerts Backed By Experts - jammulinksnews.com
Insulet Corporation Sees Spike in Bullish Option FlowTechnical Stock Breakout Predictions Signal Entry Points - metal.it
What to Expect From Insulet's Q2 2025 Earnings Report - MSN
How does Insulet Corporation compare to its industry peersPost Market Guidance With High Returns - jammulinksnews.com
What institutional investors are buying Insulet Corporation stockExceptional stock performance - jammulinksnews.com
What are the latest earnings results for Insulet CorporationTrack top-performing stocks in real-time - jammulinksnews.com
Why is Insulet Corporation stock attracting strong analyst attentionUnlock real-time stock alerts for quick profits - jammulinksnews.com
What are the technical indicators suggesting about Insulet CorporationFree Real-Time Stock Data - jammulinksnews.com
What is the dividend policy of Insulet Corporation stockUnlock the power of real-time market data - jammulinksnews.com
What analysts say about Insulet Corporation stockFree Wealth Planning Blueprint - PrintWeekIndia
Is Insulet Corporation stock overhyped or has real potentialTremendous gains - jammulinksnews.com
Is Insulet Corporation a good long term investmentRapid wealth accumulation - PrintWeekIndia
What institutions are buying Insulet Corporation stock nowExplosive portfolio gains - jammulinksnews.com
Insulet Corporation Q2 2025 Earnings Preview: Anticipating Significant GrowthNews and Statistics - IndexBox
What To Expect From Insulet's Q2 2025 Earnings Report - Barchart.com
Tubeless Insulin Pumps Market Attracts Startups Amid Booming - openPR.com
Insulin Pumps Market Outlook Report 2025, with Leading - GlobeNewswire
EOFlow’s 'EOPatch' Sales Banned in Europe - Businesskorea
Insulet granted EU-wide injunction against EOFlow in default decision by UPC - MLex
Insulin Pumps Market Outlook Report 2025, with Leading Player Profiles for Medtronic, Insulet, Tandem Diabetes Care, and More - Yahoo Finance
What drives Insulet Corporation stock priceTriple-digit wealth increases - jammulinksnews.com
Insulet Corporation Stock Analysis and ForecastFree Wealth Management Insights - jammulinksnews.com
Finanzdaten der Insulet Corporation-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.17%
1.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):